JNNN

Discussions with leaders: Czernin and Bengel interview Franz Weidinger, president of the European Society of Cardiology, about his career in advancing cardiac medicine initiatives. Page 998

FAPI-based radionuclide therapy: Ora and colleagues summarize the current status of preclinical and clinical fibroblast activation protein inhibitor–based radionuclide therapies, as well as associated dosimetry, safety profiles, and efficacy.

Immuno-PET in liver cancer: Fayn and colleagues develop and evaluate glypican-3-selective singledomain antibody PET probes for imaging liver tumors, with superior in vivo target engagement and pharmacokinetic properties. Page 1017

Late PSMA SPECT improves detection: Berliner and colleagues compare postinjection imaging timepoints in [^{99m}Tc]Tc-PSMA-I&S SPECT/CT detection of lymph node metastases in early biochemically recurrent prostate cancer. Page 1036

⁶⁸Ga-FAPI PET/CT in cholangiocarcinoma: Pabst and colleagues report on the accuracy of PET/CT with the novel cancer fibroblast–directed ⁶⁸Ga-fibroblast activation protein inhibitor-46 **PRRT and ICIs in NETs:** Esfahani and colleagues investigate whether combining peptide receptor radionuclide therapy using [¹⁷⁷Lu]DO-TATATE and immune checkpoint inhibition therapy improves treatment response in a preclinical neuroendocrine tumor model...... Page 1056

Tetravalent theranostic chelators: Abou and colleagues evaluate antibody-chelator conjugates for stability using ofatumumab, a human anti-CD20 antibody, and explore tumor targeting with a ²²⁷Th chelator conjugate in mice, highlighting potential for quantitative imaging and treatment. Page 1062

 Whole-body PET motion correction: Shiyam Sundar and colleagues introduce the Fast Algorithms for Motion Correction software, which allows correction of both rigid and nonlinear motion artifacts in dynamic whole-body images, irrespective of PET/CT system or tracer. Page 1145